
DWTX Stock Forecast & Price Target
DWTX Analyst Ratings
Bulls say
Dogwood Therapeutics is a development-stage biopharmaceutical company that is focused on developing new medicines to treat pain and neuropathy. They have a strong pipeline focused on chronic neuropathic pain and have recently announced a new long-term extension study for their Halneuron treatment. In addition, the company has licensed their anti-viral assets to PridCor Therapeutics, providing potential future milestones and royalties. While this may not have an immediate impact on the stock, it showcases the potential for future growth and development.
Bears say
Dogwood Therapeutics is a pre-revenue company focused on developing medicines for pain and neuropathy, with its pipeline mainly targeting chronic neuropathic pain and neuropathy. The upcoming topline results from the Phase 2b CINP study, expected in September, are the most important catalyst for the company in 2026 as there are currently no approved drugs for this indication, providing significant potential for market share growth in the future. However, the company has yet to generate any revenue and plans to initiate a Phase 3 pivotal study in CINP in 1H27, posing significant financial risks for investors.
This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
DWTX Analyst Forecast & Price Prediction
Start investing in DWTX
Order type
Buy in
Order amount
Est. shares
0 shares